1054 related articles for article (PubMed ID: 34731554)
1. Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum.
Uriu K; Kimura I; Shirakawa K; Takaori-Kondo A; Nakada TA; Kaneda A; Nakagawa S; Sato K;
N Engl J Med; 2021 Dec; 385(25):2397-2399. PubMed ID: 34731554
[No Abstract] [Full Text] [Related]
2. Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients.
Valleriani F; Mancuso E; Vincifori G; Teodori L; Di Marcantonio L; Spedicato M; Leone A; Savini G; Morelli D; Bonfini B; Lorusso A
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696441
[TBL] [Abstract][Full Text] [Related]
3. Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains.
Pan T; Hu Z; Hu F; Zhang Y; Liu B; Ke C; She Q; He X; Tang X; Zhang H
Cell Mol Immunol; 2021 Nov; 18(11):2560-2562. PubMed ID: 34635805
[No Abstract] [Full Text] [Related]
4. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
5. Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex.
Tang J; Grubbs G; Lee Y; Huang C; Ravichandran S; Forgacs D; Golding H; Ross TM; Khurana S
EBioMedicine; 2021 Dec; 74():103748. PubMed ID: 34902788
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
[TBL] [Abstract][Full Text] [Related]
7. Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant.
Villas-Boas LS; Paula AV; Silva ARD; Paiao HGO; Tozetto-Mendoza TR; Manuli ER; Leal FE; Ferraz ABC; Sabino EC; Bierrenbach AL; Witkin SS; Mendes-Correa MC
Clinics (Sao Paulo); 2022; 77():100068. PubMed ID: 35767900
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing Antibody Responses in COVID-19 Convalescent Sera.
Lee WT; Girardin RC; Dupuis AP; Kulas KE; Payne AF; Wong SJ; Arinsburg S; Nguyen FT; Mendu DR; Firpo-Betancourt A; Jhang J; Wajnberg A; Krammer F; Cordon-Cardo C; Amler S; Montecalvo M; Hutton B; Taylor J; McDonough KA
J Infect Dis; 2021 Jan; 223(1):47-55. PubMed ID: 33104179
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma.
Vazquez SE; Bastard P; Kelly K; Gervais A; Norris PJ; Dumont LJ; Casanova JL; Anderson MS; DeRisi JL
J Clin Immunol; 2021 Aug; 41(6):1169-1171. PubMed ID: 34009544
[No Abstract] [Full Text] [Related]
10. Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.
Bennett RS; Postnikova EN; Liang J; Gross R; Mazur S; Dixit S; Kocher G; Yu S; Georgia-Clark S; Gerhardt D; Cai Y; Marron L; Lukin VV; Holbrook MR
Viruses; 2021 May; 13(5):. PubMed ID: 34065987
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.
Bayarri-Olmos R; Idorn M; Rosbjerg A; Pérez-Alós L; Hansen CB; Johnsen LB; Helgstrand C; Zosel F; Bjelke JR; Öberg FK; Søgaard M; Paludan SR; Bak-Thomsen T; Jardine JG; Skjoedt MO; Garred P
J Immunol; 2021 Aug; 207(3):878-887. PubMed ID: 34301847
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.
Casadevall A; Henderson JP; Joyner MJ; Pirofski LA
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33621214
[No Abstract] [Full Text] [Related]
13. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 antibodies: Comparison of three high-throughput immunoassays versus the neutralization test.
Laterza R; Schirinzi A; Bruno R; Genco R; Contino R; Ostuni A; Di Serio F
Eur J Clin Invest; 2021 Jul; 51(7):e13573. PubMed ID: 33870493
[No Abstract] [Full Text] [Related]
15. Audio Interview: Aspects of Covid-19 Immunity.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Aug; 385(8):e31. PubMed ID: 34407350
[No Abstract] [Full Text] [Related]
16. Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 viruses.
Hein S; Herrlein ML; Mhedhbi I; Bender D; Haberger V; Benz N; Eisert J; Stingl J; Dreher M; Oberle D; Schulze J; Mache C; Budt M; Hildt C; Wolff T; Hildt E
Allergy; 2022 Jul; 77(7):2080-2089. PubMed ID: 34820854
[TBL] [Abstract][Full Text] [Related]
17. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea.
Nham E; Ko JH; Song KH; Choi JY; Kim ES; Kim HJ; Kim B; Lim HY; Kim KC; Jang HC; Lee KH; Song YG; Baek YJ; Ahn JY; Choi JY; Kim YC; Park YS; Choi WS; Bae S; Kim SH; Kang ES; Jeong HW; Kim SW; Kwon KT; Kim SS; Peck KR
Front Immunol; 2022; 13():968105. PubMed ID: 36211416
[TBL] [Abstract][Full Text] [Related]
19. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination.
Chen LL; Lu L; Choi CY; Cai JP; Tsoi HW; Chu AW; Ip JD; Chan WM; Zhang RR; Zhang X; Tam AR; Lau DP; To WK; Que TL; Yip CC; Chan KH; Cheng VC; Yuen KY; Hung IF; To KK
Clin Infect Dis; 2022 May; 74(9):1623-1630. PubMed ID: 34309648
[TBL] [Abstract][Full Text] [Related]
20. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
Wang Y
EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
[No Abstract] [Full Text] [Related]
[Next] [New Search]
